Plain-English translation of NCT07490769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether works better for controlling seizures when taken three times a day instead of the standard twice-daily schedule. You would take the same total amount of medication, but spread it more evenly throughout the day. The study wants to see if this new dosing pattern helps people stay seizure-free for longer periods.
Many people with epilepsy still have seizures even while taking medication. Researchers believe that spreading the medication doses more frequently throughout the day might provide better, more consistent seizure control than the current twice-daily approach.
You likely qualify if…
You likely don't qualify if…
You would take the medication three times daily for 12 months instead of your current twice-daily schedule. You'll attend regular clinic visits to check how well the medication is working and watch for any side effects. You'll also keep a daily diary to record any seizures and how you're feeling, which helps the research team track your progress.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Saudi Arabia
Large-scale testing
Sponsor
Waad Alkathiri
Enrollment target
~120 participants
Started
October 2025
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.